CD96 and neoplasm: To validate that CD96 enhances chemoresistance in BCSCs in vivo, we constructed a tumor xenograft model using BCSCs with or without CD96 knockdown.[22] The results showed that CD96 knockdown reduced tumorigenicity after serial transplantation (Figure 4E), confirming the results of our in vitro experiments (Figure S3A,B, Supporting Information).